Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Tevogen Bio Holdings Inc. (TVGN : NSDQ)

• Company Description    Tevogen Bio Holdings Inc. is a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and cancers. Tevogen Bio Holdings Inc., formerly known as SEMPER PAR ACQ, is based in Warren, New Jersey. Number of Employees: 18

• Price / Volume Information    Yesterday's Closing Price: $0.33 Daily Weekly Monthly 20 Day Moving Average: 1,439,680 shares Shares Outstanding: 198.69 (millions) Market Capitalization: $65.79 (millions) Beta: -0.79 52 Week High: $1.92 52 Week Low: $0.30 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -21.48% -21.35% 12 Week -55.14% -55.87% Year To Date 0.00% 0.00%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 15 INDEPENDENCE BOULEVARD SUITE 410 - WARREN,NJ 07059 USA ph: 877-838-6436 fax: - ir@tevogen.com https://tevogen.com

• General Corporate Information    Officers Dr. Ryan Saadi - Chief Executive Officer; Chairperson and Director Kirti Desai - Chief Financial Officer Jeffrey Feike - Director Keow Lin Goh - Director Curtis Patton - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 88165K101 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 09/01/25 Next Expected EPS Date: 04/01/26 Share - Related Items Shares Outstanding: 198.69 Most Recent Split Date: (:1) Beta: -0.79 Market Capitalization: $65.79 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 04/01/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: - Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 0.00% vs. Previous Quarter: 0.00% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 12/31/25 - - 09/30/25 - - 06/30/25 - - ROA 12/31/25 - - 09/30/25 - -761.89 06/30/25 - -775.49 Current Ratio 12/31/25 - - 09/30/25 - 0.31 06/30/25 - 0.26 Quick Ratio 12/31/25 - - 09/30/25 - 0.31 06/30/25 - 0.26 Operating Margin 12/31/25 - - 09/30/25 - - 06/30/25 - - Net Margin 12/31/25 - - 09/30/25 - - 06/30/25 - - Pre-Tax Margin 12/31/25 - - 09/30/25 - - 06/30/25 - - Book Value 12/31/25 - - 09/30/25 - -0.08 06/30/25 - -0.09 Inventory Turnover 12/31/25 - - 09/30/25 - - 06/30/25 - - Debt-to-Equity 12/31/25 - - 09/30/25 - - 06/30/25 - - Debt-to-Capital 12/31/25 - - 09/30/25 - - 06/30/25 - -

Powered by Zacks Investment Research ©